First triple therapy in one inhaler for COPD patients: treatment approach (scientific data overview)

Abstract

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of disability and mortality. The paper discusses the role of single inhaler triple therapy in COPD maintenance treatment. Trelegy Ellipta - the first fixed triple combination registered in Russia - is taken as an example. Below we deliberate on classes of components and their mechanism of action, clinical effectiveness, influence on exacerbations' risk, functional and patient-reported outcomes, safety, and mortality reduction. We also discuss the approaches for triple therapy administration to COPD patients recommended by a row of national and global guidelines.